collection
https://read.qxmd.com/read/31563498/risk-reduction-and-right-heart-reverse-remodeling-by-upfront-triple-combination-therapy-in-pulmonary-arterial%C3%A2-hypertension
#1
JOURNAL ARTICLE
Michele D'Alto, Roberto Badagliacca, Paola Argiento, Emanuele Romeo, Andrea Farro, Silvia Papa, Berardo Sarubbi, Maria Giovanna Russo, Carmine Dario Vizza, Paolo Golino, Robert Naeije
BACKGROUND: Combinations of therapies are currently recommended for patients with severe pulmonary arterial hypertension (PAH), and excellent results have been reported with triple upfront combination of these drugs. We evaluated the effects of this approach on right ventricular (RV) function and outcome in patients with severe PAH. METHODS: Twenty-one patients (age, 44 ± 15 years) with newly diagnosed high-risk idiopathic PAH that was nonreversible by the inhalation of nitric oxide were treated upfront with a combination of ambrisentan, tadalafil, and subcutaneous treprostinil between 2014 and 2018...
February 2020: Chest
https://read.qxmd.com/read/30174448/insight-into-acinetobacter-baumannii-pathogenesis-global-resistance-mechanisms-of-resistance-treatment-options-and-alternative-modalities
#2
REVIEW
Muhammad Asif, Iqbal Ahmad Alvi, Shafiq Ur Rehman
Acinetobacter baumannii , once considered a low-category pathogen, has emerged as an obstinate infectious agent. The scientific community is paying more attention to this pathogen due to its stubbornness to last resort antimicrobials, including carbapenems, colistin, and tigecycline, its high prevalence of infections in the hospital setting, and significantly increased rate of community-acquired infections by this organism over the past decade. It has given the fear of pre-antibiotic era to the world. To further enhance our understanding about this pathogen, in this review, we discuss its taxonomy, pathogenesis, current treatment options, global resistance rates, mechanisms of its resistance against various groups of antimicrobials, and future therapeutics...
2018: Infection and Drug Resistance
https://read.qxmd.com/read/29910040/sodium-bicarbonate-therapy-for-patients-with-severe-metabolic-acidaemia-in-the-intensive-care-unit-bicar-icu-a-multicentre-open-label-randomised-controlled-phase-3-trial
#3
MULTICENTER STUDY
Samir Jaber, Catherine Paugam, Emmanuel Futier, Jean-Yves Lefrant, Sigismond Lasocki, Thomas Lescot, Julien Pottecher, Alexandre Demoule, Martine Ferrandière, Karim Asehnoune, Jean Dellamonica, Lionel Velly, Paër-Sélim Abback, Audrey de Jong, Vincent Brunot, Fouad Belafia, Antoine Roquilly, Gérald Chanques, Laurent Muller, Jean-Michel Constantin, Helena Bertet, Kada Klouche, Nicolas Molinari, Boris Jung
BACKGROUND: Acute acidaemia is frequently observed during critical illness. Sodium bicarbonate infusion for the treatment of severe metabolic acidaemia is a possible treatment option but remains controversial, as no studies to date have examined its effect on clinical outcomes. Therefore, we aimed to evaluate whether sodium bicarbonate infusion would improve these outcomes in critically ill patients. METHODS: We did a multicentre, open-label, randomised controlled, phase 3 trial...
July 7, 2018: Lancet
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.